REVELATION BIOSCIENCES Files 8-K on Shareholder Vote Matters

TL;DR

**REVB filed an 8-K about shareholder votes, signaling potential big changes ahead.**

AI Summary

REVELATION BIOSCIENCES, INC. filed an 8-K on January 22, 2024, reporting an event that occurred on January 17, 2024. The filing indicates the submission of matters to a vote of security holders and includes financial statements and exhibits. This matters to investors because it signals potential changes or decisions that could impact the company's future operations, capital structure, or strategic direction, which could affect stock valuation.

Why It Matters

This filing indicates that shareholders are voting on important company matters, which could lead to significant operational or financial changes. Investors should monitor the outcome of these votes as they directly influence the company's future trajectory.

Risk Assessment

Risk Level: medium — The filing indicates a vote of security holders, which could lead to significant changes, but the specific outcomes and their impact are not yet disclosed, creating uncertainty.

Analyst Insight

A smart investor would closely monitor subsequent filings from REVELATION BIOSCIENCES, INC. for the results of the security holder vote and any details on the matters voted upon, as these could significantly impact the company's future.

Key Numbers

• 2024-01-17 — Earliest Event Reported Date (Indicates when the event requiring the 8-K filing occurred.)
• 2024-01-22 — Filing Date (The date the 8-K was officially submitted to the SEC.)

Key Players & Entities

• REVELATION BIOSCIENCES, INC. (company) — the registrant filing the 8-K
• January 17, 2024 (date) — date of the earliest event reported
• January 22, 2024 (date) — date the 8-K was filed
• 001-39603 (other) — Commission File Number
• 84-3898466 (other) — IRS Employer Identification No.
• 4660 La Jolla Village Drive Suite 100, San Diego, California, 92122 (other) — principal executive offices address
• 650-800-3717 (other) — registrant's telephone number

Forward-Looking Statements

• REVELATION BIOSCIENCES, INC. will likely issue further disclosures regarding the outcomes of the security holder vote. (REVELATION BIOSCIENCES, INC.) — high confidence, target: 2024-03-31

FAQ

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share REVB The Nasdaq Stock Mar
• $402.50 — of common stock at an exercise price of $402.50 per share REVBW The Nasdaq Stock Ma

Filing Documents

• revb-20240117.htm (8-K) — 54KB
• 0000950170-24-006051.txt ( ) — 207KB
• revb-20240117.xsd (EX-101.SCH) — 48KB
• revb-20240117_htm.xml (XML) — 7KB

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. On January 17, 2024, Revelation Biosciences, Inc. (the “Company”), held a special meeting of stockholders (the “Special Meeting”). At the Special Meeting, the stockholders voted and approved proposals to (1) grant discretionary authority to our board of directors to (i) amend our certificate of incorporation to combine outstanding shares of our common stock into a lesser number of outstanding shares, or a “reverse stock split,” at a specific ratio within a range of one-for-2 to a maximum of a one-for-50 split, with the exact ratio to be determined by our board of directors in its sole discretion; and (ii) effect the reverse stock split, if at all, within one year of the date the proposal is approved by stockholders, and (2) approve the adjournment of the Special Meeting to the extent there are insufficient proxies at the Special Meeting to approve the Reverse Stock Split. At the Special Meeting of the Company, a total of 2,244,048 shares of the Company’s common stock, out of a total of 6,297,303 shares of common stock issued and outstanding and entitled to vote at the Special Meeting, as of the record date for the Special Meeting, were present virtually, or represented by valid proxy at the Special Meeting, constituting a quorum. As previously described in in the Company’s Proxy Statement, holders of the Company’s common stock were entitled to one vote per share on each of the two proposals. The following proposals, each as described further in the Proxy Statement, were voted upon by the stockholders: Proposal 1 – Reverse Stock Split Stockholders approved the board of directors to effect a Reverse Stock Split of the outstanding shares of our common stock within one (1) year of January 17, 2024, at a specific ratio within a range of one-for-2 to a maximum of a one-for-50 split, with the specific ratio to be fixed within thi

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REVELATION BIOSCIENCES, INC. Date: January 22, 2024 By: /s/ Chester S. Zygmont, III Chester S. Zygmont, III Chief Financial Officer (principal financial and accounting officer)

View Full Filing

View this 8-K filing on SEC EDGAR